Obesity, Type 2 Diabetes may Soon be Reversed with Gene Therapy

by Iswarya on  August 30, 2019 at 1:00 PM Genetics & Stem Cells News
RSS Email Print This Page Comment bookmark
Font : A-A+

Gene therapy has been used in mice to successfully reverse obesity and insulin resistance, as well as other markers of type 2 diabetes, reports a new study. The findings of the study are published in the journal Genome Research.
Obesity, Type 2 Diabetes may Soon be Reversed with Gene Therapy
Obesity, Type 2 Diabetes may Soon be Reversed with Gene Therapy

The obesity epidemic affects nearly half a billion people worldwide, many of them children. Obesity-related diseases, including heart disease, stroke, type 2 diabetes, and cancer, are a leading cause of preventable death. Obesity is caused by both genetic and environmental factors, confounding the development of effective anti-obesity drugs, which exhibit severe off-target effects.

Show Full Article


In a study, researchers developed a gene therapy that specifically reduces fat tissue and reverses obesity-related metabolic disease in obese mice.

To overcome the side effects of current anti-obesity drugs, researchers Jee Young Chung and colleagues developed a specific gene silencing therapy against a fatty acid metabolism gene, Fabp4.

Researchers used a CRISPR interference system wherein catalytically dead Cas9 protein, and single-guide RNA was targeted to white adipocytes with a tissue-specific fusion peptide. The complex is internalized with little toxicity to the cells, and upon internalization, the molecule complex decreases the expression of Fabp4 and reduces lipid storage in adipocytes. Demonstrating that this delivery method performed well in cells, Chung, and colleagues tested their therapy on obese mice. Mice were fed a diet high in fat leading to obesity and insulin resistance.

Fabp4 repression resulted in a 20% reduction in body weight and improved insulin resistance and inflammation after just six weeks of treatment. Additional systemic improvements were observed, including a reduction in fatty lipid deposition in the liver and reduced circulating triglycerides.

The current standard FDA-approved treatment showed just 5% of body weight loss after one year of treatment in humans. However, while this therapy displays promising results in mice, further studies are required before it can be used in clinical treatment against human disease. Importantly, this work highlights the advances in precision gene-editing technology, which can be translated to other types of therapies.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive